Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2023 | May 05, 2023 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-40209 | |
Entity Registrant Name | Heliogen, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 85-4204953 | |
Entity Address, Address Line One | 130 West Union Street | |
Entity Address, City or Town | Pasadena | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 91103 | |
City Area Code | 626 | |
Local Phone Number | 720-4530 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 196,847,953 | |
Entity Central Index Key | 0001840292 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Common Stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common stock, $0.0001 par value per share | |
Trading Symbol | HLGN | |
Security Exchange Name | NYSE | |
Warrants | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants, each whole warrant exercisable for shares of Common stock at an exercise price of $11.50 per share | |
Trading Symbol | HLGN.W | |
Security Exchange Name | NYSE | |
Preferred Share Purchase Right | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Preferred Share Purchase Rights | |
No Trading Symbol Flag | true | |
Security Exchange Name | NYSE |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
ASSETS | ||
Cash and cash equivalents | $ 39,215 | $ 45,719 |
Short-term restricted cash | 528 | 655 |
Investments, available-for-sale | 80,700 | 97,504 |
Receivables | 10,646 | 9,195 |
Inventories | 2,900 | 2,442 |
Prepaid and other current assets | 5,092 | 3,306 |
Total current assets | 139,081 | 158,821 |
Operating lease right-of-use assets | 14,373 | 14,772 |
Property, plant and equipment, net | 6,777 | 7,071 |
Goodwill and intangible assets, net | 135 | 1,160 |
Long-term restricted cash | 1,500 | 1,500 |
Other long-term assets | 8,104 | 8,295 |
Total assets | 169,970 | 191,619 |
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
Trade payables | 3,285 | 6,921 |
Contract liabilities | 10,966 | 10,348 |
Contract loss provisions | 28,360 | 28,418 |
Accrued expenses and other current liabilities | 5,945 | 5,602 |
Total current liabilities | 48,556 | 51,289 |
Operating lease liabilities, non-current | 13,483 | 13,921 |
Warrant liabilities | 338 | 642 |
Other long-term liabilities | 1,565 | 443 |
Total liabilities | 63,942 | 66,295 |
Commitments and contingencies (Note 13) | ||
Shareholders’ equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares outstanding as of March 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.0001 par value; 500,000,000 shares authorized and 195,732,947 shares issued and outstanding (excluding restricted shares of 50,331) as of March 31, 2023; 192,924,429 shares issued and outstanding (excluding restricted shares of 59,770) as of December 31, 2022 | 19 | 19 |
Additional paid-in capital | 425,590 | 434,478 |
Accumulated other comprehensive loss | (457) | (593) |
Accumulated deficit | (319,124) | (308,580) |
Total shareholders’ equity | 106,028 | 125,324 |
Total liabilities and shareholders’ equity | $ 169,970 | $ 191,619 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 195,732,947 | 192,924,429 |
Common stock, shares outstanding (in shares) | 195,732,947 | 192,924,429 |
Unvested equity instrument outstanding (in shares) | 50,331 | 59,770 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Services revenue | $ 866 | $ 2,044 |
Grant revenue | 1,071 | 1,495 |
Total revenue | 1,937 | 3,539 |
Cost of revenue: | ||
Cost of services revenue (including depreciation) | 941 | 2,592 |
Cost of grant revenue | 1,071 | 1,495 |
Provision for contract losses | 370 | 33,737 |
Total cost of revenue | 2,382 | 37,824 |
Gross loss | (445) | (34,285) |
Operating expenses: | ||
Selling, general and administrative | 4,165 | 20,062 |
Research and development | 5,260 | 9,375 |
Impairment charges | 1,008 | 0 |
Total operating expenses | 10,433 | 29,437 |
Operating loss | (10,878) | (63,722) |
Interest income, net | 283 | 194 |
Gain on warrant remeasurement | 304 | 4,026 |
Other expense, net | (253) | (76) |
Net loss before taxes | (10,544) | (59,578) |
Benefit for income taxes | 0 | 610 |
Net loss | $ (10,544) | $ (58,968) |
Loss per share: | ||
Loss per share – Basic (in dollars per share) | $ (0.05) | $ (0.32) |
Loss per share – Diluted (in dollars per share) | $ (0.05) | $ (0.32) |
Weighted average number of shares outstanding – Basic (in shares) | 196,899,292 | 184,031,015 |
Weighted average number of shares outstanding – Diluted (in shares) | 196,899,292 | 184,031,015 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (10,544) | $ (58,968) |
Other comprehensive income (loss), net of taxes: | ||
Unrealized gains (losses) on available-for-sale securities | 173 | (379) |
Cumulative translation adjustment | (37) | (1) |
Total other comprehensive income (loss), net of taxes | 136 | (380) |
Comprehensive loss | $ (10,408) | $ (59,348) |
Consolidated Statements of Shar
Consolidated Statements of Shareholders’ Equity - USD ($) $ in Thousands | Total | Vendor agreements | Customer agreements | Common Stock | Additional Paid-in Capital | Additional Paid-in Capital Vendor agreements | Additional Paid-in Capital Customer agreements | Accumulated Other Comprehensive Loss | Accumulated Deficit |
Beginning balance (in shares) at Dec. 31, 2021 | 183,367,037 | ||||||||
Beginning balance at Dec. 31, 2021 | $ 214,058 | $ 18 | $ 380,624 | $ (4) | $ (166,580) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (58,968) | (58,968) | |||||||
Other comprehensive income (loss) | (380) | (380) | |||||||
Share-based compensation | 12,982 | 12,982 | |||||||
Stock options exercised (in shares) | 2,754,244 | ||||||||
Stock options exercised | 272 | $ 1 | 271 | ||||||
Issue of warrants | $ 9,339 | $ 9,339 | |||||||
Ending balance (in shares) at Mar. 31, 2022 | 186,121,281 | ||||||||
Ending balance at Mar. 31, 2022 | 177,303 | $ 19 | 403,216 | (384) | (225,548) | ||||
Beginning balance (in shares) at Dec. 31, 2021 | 183,367,037 | ||||||||
Beginning balance at Dec. 31, 2021 | 214,058 | $ 18 | 380,624 | (4) | (166,580) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (142,000) | ||||||||
Ending balance (in shares) at Dec. 31, 2022 | 192,924,429 | ||||||||
Ending balance at Dec. 31, 2022 | 125,324 | $ 19 | 434,478 | (593) | (308,580) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net loss | (10,544) | (10,544) | |||||||
Other comprehensive income (loss) | 136 | 136 | |||||||
Share-based compensation | (9,306) | (9,306) | |||||||
Restricted stock vestings (in shares) | 1,210,801 | ||||||||
Stock options exercised (in shares) | 1,597,717 | ||||||||
Stock options exercised | 235 | 235 | |||||||
Issue of warrants | $ 107 | $ 76 | $ 107 | $ 76 | |||||
Ending balance (in shares) at Mar. 31, 2023 | 195,732,947 | ||||||||
Ending balance at Mar. 31, 2023 | $ 106,028 | $ 19 | $ 425,590 | $ (457) | $ (319,124) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net loss | $ (10,544) | $ (58,968) | $ (142,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 601 | 760 | |
Impairment charges | 1,008 | 0 | |
Share-based compensation | (9,306) | 12,982 | |
Change in fair value of warrants | (304) | (4,026) | |
Change in fair value of contingent consideration | 1,125 | 14 | |
Deferred income taxes | 0 | (611) | |
Non-cash operating lease expense | 400 | 428 | |
Other non-cash operating activities | (570) | 101 | |
Changes in assets and liabilities: | |||
Receivables | (1,497) | (9,693) | |
Inventories | (458) | 0 | |
Prepaid and other current assets | (1,786) | (3,802) | |
Trade payables and accrued liabilities | (3,084) | 456 | |
Contract liabilities | 705 | 6,811 | |
Provision for contract losses, net | (77) | 33,766 | |
Other non-current assets and liabilities | (345) | (891) | |
Net cash used in operating activities | (24,132) | (22,673) | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Capital expenditures | (527) | (1,360) | |
Purchases of available-for-sale securities | (44,520) | (122,468) | |
Maturities of available-for-sale securities | 62,300 | 21,100 | |
Net cash provided by (used in) investing activities | 17,253 | (102,728) | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Proceeds from exercise of stock options | 248 | 209 | |
Other financing costs | 0 | (1,274) | |
Net cash provided by (used in) financing activities | 248 | (1,065) | |
Decrease in cash, cash equivalents and restricted cash | (6,631) | (126,466) | |
Cash, cash equivalents and restricted cash at the beginning of the period | 47,874 | 191,581 | 191,581 |
Cash, cash equivalents and restricted cash at the end of the period | 41,243 | 65,115 | 47,874 |
Reconciliation of cash, cash equivalents and restricted cash: | |||
Cash and cash equivalents | 39,215 | 63,615 | 45,719 |
Short-term restricted cash | 528 | 0 | 655 |
Long-term restricted cash | 1,500 | 1,500 | 1,500 |
Total cash, cash equivalents and restricted cash | 41,243 | 65,115 | $ 47,874 |
Non-cash investing and financing activities: | |||
Fair value of Project Warrants and Collaboration Warrants recognized in equity | 76 | 9,339 | |
Capital expenditures incurred but not yet paid | $ 56 | $ 19 |
Organization and Basis of Prese
Organization and Basis of Presentation | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Basis of Presentation | Note 1—Organization and Basis of Presentation Background Heliogen, Inc. and its subsidiaries (collectively, “Heliogen” or the “Company”), is involved in the development and commercialization of next generation concentrated solar energy. We are developing a modular, artificial intelligence (“AI”)-enabled, concentrated solar energy plant that will use an array of mirrors to reflect sunlight and capture, concentrate, store and convert it into cost-effective energy on demand. Unless otherwise indicated or the context requires otherwise, references in our consolidated financial statements to “we,” “us,” or “our” and similar expressions refer to Heliogen. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, these unaudited consolidated financial statements do not include all information or notes required by GAAP for annual financial statements. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for fair statement. The results reported in these unaudited consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year. These unaudited consolidated financial statements should be read in conjunction with the annual financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 29, 2023. Certain immaterial prior period amounts have been reclassified to conform to current period presentation. Such changes did not have a material impact on our financial position or results of operation. The Company has evaluated whether there were conditions and events, considered in the aggregate, which raise substantial doubt as to the Company’s ability to continue as a going concern within one year after the original issuance date of the consolidated financial statements. During the three months ended March 31, 2023 and the year ended December 31, 2022, the Company incurred net losses of $10.5 million and $142.0 million, respectively. The Company expects to continue to generate operating losses in the next few years. As of March 31, 2023, the Company had liquidity of $119.9 million, consisting of $39.2 million of cash and cash equivalents and $80.7 million of investments, and no substantial debt. Management believes it has the ability to manage operating costs and capital expenditures such that its existing cash, cash equivalents and investments will be sufficient to fund its operations and capital expenditures for the next twelve months following the filing of this Quarterly Report on Form 10-Q. The Company’s long-term liquidity will depend on its ability to (i) successfully complete current projects within budget, (ii) raise additional capital through the issuance of additional equity or debt securities, (iii) sign additional projects at a profit, (iv) obtain funding and receive payment for research and development (“R&D”) projects under government subsidies, (v) implement project cost reductions to reduce the expected cash outflows and (vi) manage operating costs. There is no assurance that the Company will be successful in achieving all or any of these items. If the Company is unsuccessful in achieving all or any of these items, the Company may be forced to delay, reduce or eliminate some or all of its R&D programs, product expansion or commercialization efforts, any of which could adversely affect its business prospects, or the Company may be unable to continue operations. Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to inputs used to recognize revenue over time, accounting for income taxes, fair values of share-based compensation, lease liabilities, warrant liabilities, contingent consideration, goodwill impairments and long-lived asset impairments. Despite our intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions. Recent Accounting Standards In January 2017, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which eliminates the second step of the previous two-step quantitative test of goodwill impairment. Under the new guidance, the quantitative test consists of a single step in which the carrying amount of the reporting unit is compared to its fair value. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the amount of the impairment would be limited to the total amount of goodwill allocated to the reporting unit. The guidance does not affect the existing option to perform the qualitative assessment for a reporting unit to determine whether the quantitative impairment test is necessary. The new guidance will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. The Company adopted this guidance on January 1, 2023 and it did not have a material impact on the Company’s consolidated financial statements. |
Revenue
Revenue | 3 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Note 2—Revenue Disaggregated Revenue The following table provides information about disaggregated revenue: Three Months Ended March 31, $ in thousands 2023 2022 Project revenue $ 816 $ 1,991 Engineering services revenue 50 53 Total services revenue 866 2,044 Grant revenue 1,071 1,495 Total revenue $ 1,937 $ 3,539 Services Revenue Project revenue consists of amounts recognized under contracts with customers for the development, construction and delivery of commercial-scale concentrated solar energy facilities. Engineering services revenue consists of amounts recognized under contracts with customers for the provision of engineering, R&D or other similar services in our field of expertise. Revenue recognized during the three months ended March 31, 2023 and 2022 includes non-governmental customers in the United States (“U.S.”) and Europe. During the three months ended March 31, 2023 and 2022, the Company recognized project revenue of $0.8 million and $2.0 million, respectively, associated with a commercial-scale demonstration agreement (“CSDA”) executed with Woodside Energy (USA) Inc. (“Woodside”) in March 2022. Grant Revenue During the three months ended March 31, 2023 and 2022, the Company recognized grant revenue under the Company’s award from the U.S. Department of Energy (the “DOE Award”) of $1.1 million and $1.5 million, respectively, related to costs incurred during such periods that are reimbursable under the DOE Award. Provision for Contract Losses During the three months ended March 31, 2023, we recognized a total provision for contract losses of $0.4 million associated with our Germany operations. During the three months ended March 31, 2023, we amortized $0.4 million of the previously recognized contract loss provisions as a reduction to cost of services revenue incurred during the three months ended March 31, 2023 based on percentages of completion. During the three months ended March 31, 2022, we recognized a total provision for contract losses of $33.7 million driven primarily by the CSDA. Performance Obligations Revenue recognized under contracts with customers relates solely to the performance obligations satisfied during the three months ended March 31, 2023 with no revenue recognized from performance obligations satisfied in prior periods. As of March 31, 2023, we had approximately $38.5 million of transaction prices allocated to remaining performance obligations from our customer contracts, we expect to recognize approximately 21% as revenue over the next 12 months and the remainder to be recognized thereafter through 2026. Receivables Receivables consisted of the following: $ in thousands March 31, 2023 December 31, 2022 Trade receivables $ 1,593 $ 1,119 Grant receivables: Unbilled 6,681 5,610 Other grant receivables 1,578 1,578 Total grant receivables 8,259 7,188 Contract assets 529 560 Other receivables 265 328 Total receivables $ 10,646 $ 9,195 Contract Assets and Liabilities The following table outlines the activity related to contract assets, which is included in total receivables on our consolidated balance sheets: $ in thousands Balance as of December 31, 2022 $ 560 Foreign currency translation adjustments 12 Other (43) Balance as of March 31, 2023 $ 529 The following table outlines the activity related to contract liabilities: $ in thousands Balance as of December 31, 2022 $ 10,348 Payments received in advance of performance 1,464 Revenue recognized (774) Recognition of consideration payable associated with Project Warrants (76) Other 4 Balance as of March 31, 2023 $ 10,966 Customer Concentrations For the three months ended March 31, 2023 and 2022, two customers each comprised greater than 10% of our total revenue and collectively represented 97% and 99%, respectively, of our total revenue. As of March 31, 2023 and December 31, 2022, two customers each comprised greater than 10% of our total receivables and collectively represented 92% and 90%, respectively, of our total receivables. |
Warrants
Warrants | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Warrants | Note 3—Warrants Public Warrants and Private Warrants The Company’s warrant liabilities as of March 31, 2023 include public warrants (the “Public Warrants”) and private placement warrants (the “Private Warrants,” and together with the Public Warrants, the “Public and Private Warrants”). The Public Warrants and Private Warrants permit warrant holders to purchase in the aggregate approximately 8.3 million shares and approximately 0.2 million shares, respectively, of the Company’s common stock at an exercise price of $11.50 per share. The Public and Private Warrants became exercisable on March 18, 2022 and expire on December 30, 2026, or earlier upon redemption or liquidation. The Public and Private Warrants are recorded as liabilities on the consolidated balance sheets and measured at fair value at each reporting date, with the change in fair value reported in gain (loss) on warrant remeasurement on the consolidated statements of operations. Project Warrants In connection with the concurrent execution of the CSDA with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase approximately 0.9 million shares of the Company’s common stock at an exercise price of $0.01 per share (the “Project Warrants”). The Project Warrants expire upon the earlier of a change in control of the Company or March 28, 2027 and vest pro rata with certain payments required to be made by the customer under the CSDA. The fair value of the Project Warrants upon issuance was $4.96 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price. The Project Warrants are recorded as equity on the consolidated balance sheets. During the three months ended March 31, 2022, the total consideration payable to the customer of $4.5 million for the Project Warrants reduced the transaction price associated with the customer’s contract and the Company recognized $0.2 million as an increase to additional paid-in capital to reflect the attribution of the Project Warrants’ fair value in a manner similar to revenue recognized under the customer’s contract. During the three months ended March 31, 2023, approximately 0.1 million of Project Warrants vested with a value of $0.1 million, which was recognized as additional paid-in capital. No Project Warrants vested during the three months ended March 31, 2022. From the issuance date of the Project Warrants on March 28, 2022 to March 31, 2023, a total of approximately 0.4 million of Project Warrants vested with a total value of $0.8 million, which was recognized as additional paid-in capital. Collaboration Warrants In connection with the concurrent execution of a collaboration agreement (the “Collaboration Agreement”) with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase approximately 3.6 million shares of the Company’s common stock at an exercise price of $0.01 per share (the “Collaboration Warrants”). Under the Collaboration Agreement, Woodside will assist us in defining product offerings that use our modular technology for potential customers in Australia. The Collaboration Warrants expire upon the earlier of a change in control of the Company or March 28, 2027. Of these warrants, (i) approximately 1.8 million warrants vested immediately upon execution of the Collaboration Agreement and (ii) approximately 1.8 million warrants will vest based on certain specified performance goals under the Collaboration Agreement. The fair value of the Collaboration Warrants upon issuance was $4.96 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price. The Collaboration Warrants are recorded as equity on the consolidated balance sheets and the related expense is being recognized ratably as selling, general and administrative (“SG&A”) expense over the estimated service period. As of March 31, 2023, the Company has a prepaid expense of $6.8 million for the Collaboration Warrants, of which $2.0 million was classified as current and $4.8 million was classified as long-term. During the three months ended March 31, 2023, we recognized $0.5 million SG&A expense related to the vesting of the Collaboration Warrants. The Company did not recognize any SG&A expense during the three months ended March 31, 2022 for the Collaboration Warrants. As of March 31, 2023, the remaining estimated period is approximately 3.4 years. Vendor Warrants On April 19, 2022, the Company issued warrants to purchase approximately 0.1 million shares of the Company’s common stock, at an exercise price of $0.01 per share (“Vendor Warrants”), to a vendor as compensation for services to be performed by the vendor. The Vendor Warrants vest in twelve equal monthly installments. The Vendor Warrants are recorded as equity on the consolidated balance sheets and had a fair value upon issuance of $0.3 million, to be recognized ratably over one year as SG&A expense. During the three months ended March 31, 2023, the Company recognized $0.1 million of share-based compensation expense, included in SG&A, related to the portion of the Vendor Warrants that vested during the period. As of April 2023, the Vendor Warrants are fully vested. |
Investments
Investments | 3 Months Ended |
Mar. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | Note 4—Investments Investments in fixed maturity securities are classified as available-for-sale. The primary objectives of our investment portfolio are to maintain the safety of our invested capital, provide prudent levels of liquidity to accommodate operational and capital needs and maintain an acceptable level of risk. These risks include credit risk, interest rate risk and concentration risk, which are mitigated through the use of various well-established financial institutions as well as an investments portfolio consisting of very liquid and high credit quality instruments. The following table summarizes our investments, available-for-sale: March 31, 2023 December 31, 2022 $ in thousands Amortized Unrealized Fair Amortized Unrealized Fair Corporate bonds $ — $ — $ — $ 3,997 $ (22) $ 3,975 Commercial paper 14,927 (4) 14,923 10,837 (3) 10,834 U.S. treasury bills 65,909 (132) 65,777 82,979 (284) 82,695 Total investments, available-for-sale $ 80,836 $ (136) $ 80,700 $ 97,813 $ (309) $ 97,504 The cost of securities sold is based on the specific-identification method. During the three months ended March 31, 2023 and 2022, there were no sales of investments. There were no credit losses recognized during the three months ended March 31, 2023 and 2022 and no allowance for credit losses as of March 31, 2023 and December 31, 2022. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Note 5—Fair Value of Financial Instruments The Company’s assets and liabilities measured at fair value on a recurring basis are summarized in the following table by fair value measurement level: $ in thousands Level March 31, 2023 December 31, 2022 Assets: Investments, available-for-sale 1 $ 80,700 $ 97,504 Liabilities: Public Warrants (1) 1 $ 329 $ 625 Private Warrants (1) 2 9 17 Contingent consideration (2) 3 1,478 353 ________________ (1) Included in warrant liabilities on the consolidated balance sheets. (2) Included in other long-term liabilities on the consolidated balance sheets. Private Warrants. The fair value of the Private Warrants approximates the fair value of the Public Warrants due to the existence of similar redemption provisions. As a result, the Company has determined that the fair value of the Private Warrants at a specific date would be similar to that of the Public Warrants, and thus is also determined by using the closing price of the Public Warrants, which was $0.04 as of March 31, 2023. Contingent Consideration. The contingent consideration was measured at fair value using a probability-weighted cash-flow method. The key inputs used in the valuation for the contingent consideration as of March 31, 2023 included the timing and probability of payment. The following table summarizes the activities of our Level 3 fair value measurements: Three Months Ended March 31, $ in thousands 2023 2022 Beginning balance $ 353 $ 2,009 Change in fair value (1) 1,125 14 Ending balance $ 1,478 $ 2,023 ________________ (1) The changes in the fair value of the contingent consideration are reported in other income (expense), net on our consolidated statements of operations. |
Property, Plant and Equipment
Property, Plant and Equipment | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Note 6—Property, Plant & Equipment Major classes of property, plant and equipment, consisted of the following: $ in thousands Estimated Useful Lives in Years March 31, 2023 December 31, 2022 Leasehold improvements 5 — 7 $ 2,936 $ 2,931 Computer equipment 2 — 3 2,151 2,124 Machinery, vehicles and other equipment 5 — 10 3,739 3,528 Furniture and fixtures 2 — 5 654 646 Construction in progress 453 419 Total property, plant and equipment 9,933 9,648 Accumulated depreciation (3,156) (2,577) Total property, plant and equipment, net $ 6,777 $ 7,071 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | Note 7—Goodwill and Intangible Assets Goodwill The Company had goodwill related to the acquisition of HelioHeat GmbH, a private limited liability company in Germany engaged in the development, planning and construction of renewable energy systems and components, including a novel solar receiver. During the first quarter of 2023, the Company performed a goodwill impairment assessment driven by the sustained decline in the Company’s market capitalization below the Company’s carrying value. Management concluded that it is more likely than not that the fair value of our reporting unit was less than its carrying amount as of March 31, 2023. As a result of the impairment test performed, the Company fully impaired goodwill and recognized a $1.0 million charge during the three months ended March 31, 2023. There were no impairments of goodwill recognized in prior periods. The changes in the carrying amount of goodwill are as follows: $ in thousands Balance as of December 31, 2022 $ 1,004 Currency translation adjustments 4 Impairment (1,008) Balance as of March 31, 2023 $ — Intangible Assets Intangible assets consisted of the following: March 31, 2023 December 31, 2022 $ in thousands Useful Life in Years Gross Carrying Amounts Accumulated Amortization Intangible Assets, Net Gross Carrying Amounts Accumulated Amortization and Impairment Intangible Assets, Net Acquired developed technology rights (1) 5 $ — $ — $ — $ 3,799 $ (3,799) $ — Software licenses 3 259 (124) 135 259 (103) 156 Total $ 259 $ (124) $ 135 $ 4,058 $ (3,902) $ 156 ________________ (1) Gross carrying amount for December 31, 2022 reflects currency translation adjustments of $0.4 million. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 3 Months Ended |
Mar. 31, 2023 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | Note 8—Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: $ in thousands March 31, 2023 December 31, 2022 Payroll and other employee benefits $ 532 $ 811 Professional fees 1,309 729 Research, development and project costs 1,346 1,313 Inventory in-transit — 654 Operating lease liabilities, current portion 1,608 1,570 Other accrued expenses 1,150 525 Total accrued expenses and other current liabilities $ 5,945 $ 5,602 |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 9—Income Taxes We calculate our quarterly tax provision pursuant to the guidelines in Accounting Standards Codification (“ASC”) 740, Income Taxes . ASC 740 requires companies to estimate the annual effective tax rate for current year ordinary income. In calculating the effective tax rate, permanent differences between financial reporting and taxable income are factored into the calculation, and temporary differences are not. The estimated annual effective tax rate represents the Company’s estimate of the tax provision in relation to the best estimate of pre-tax ordinary income or loss. The estimated annual effective tax rate is then applied to year-to-date ordinary income or loss to calculate the year-to-date interim tax provision. The relationship between our income tax provision or benefit and our pre-tax book income or loss can vary significantly from period to period considering, among other factors, the overall level of pre-tax book income or loss and changes in the blend of jurisdictional income or loss that is taxed at different rates and changes in valuation allowances. The income tax benefit of $0.6 million for the three months ended March 31, 2022, is primarily attributable to our Germany operations. Any income tax benefit associated with the pre-tax loss for the three months ended March 31, 2023 and 2022, resulting primarily from the U.S. jurisdiction, is offset by a full valuation allowance. In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the analysis of federal and state deferred tax balances, future tax projections and availability of taxable income in the carryback period, we recorded a full valuation allowance against the federal and state deferred tax assets for the three months ended March 31, 2023 and the year ended December 31, 2022. The Company is subject to the provisions of ASC Subtopic 740-10, Accounting for Uncertainty in Income Taxes . This standard defines the threshold for recognizing the benefits of tax return positions in the financial statements as more-likely-than-not to be sustained by the relevant taxing authority and requires measurement of a tax position meeting the more-likely-than-not criterion, based on the largest benefit that is more than 50% likely to be realized. If upon performance of an assessment pursuant to this subtopic, management determines that uncertainties in tax positions exist that do not meet the minimum threshold for recognition of the related tax benefit, a liability is recorded in the consolidated financial statements. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as a component of income tax expense. We do not have material unrecognized tax benefits for uncertain tax positions. |
Loss Per Share
Loss Per Share | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Loss Per Share | Note 10—Loss per Share Basic and diluted loss per share (“EPS”) were as follows: Three Months Ended March 31, $ in thousands, except share and per share data 2023 2022 Numerator: Net loss $ (10,544) $ (58,968) Denominator: Weighted-average common shares outstanding 194,650,065 183,949,912 Weighted-average impact of warrants (1) 2,249,227 81,103 Denominator for basic EPS – weighted-average shares 196,899,292 184,031,015 Effect of dilutive securities — — Denominator for diluted EPS – weighted-average shares 196,899,292 184,031,015 EPS – Basic and Diluted $ (0.05) $ (0.32) ________________ (1) Warrants that have a $0.01 exercise price are assumed to be exercised when vested because common shares issued for little consideration upon exercise are included in outstanding shares for the purposes of computing basic and diluted EPS. The following securities were excluded from the calculation of loss per share as their impact would be anti-dilutive: Three Months Ended March 31, 2023 2022 Stock options 19,533,368 37,429,240 Shares issuable related to the employee stock purchase plan 440,502 — Unvested restricted stock units 11,770,288 — Restricted shares issued upon the early exercise of unvested stock options 50,331 5,150,369 Unvested warrants 2,312,026 — Vested warrants 8,566,656 8,566,666 |
Share-based Compensation
Share-based Compensation | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based Compensation | Note 11—Share-based Compensation The Heliogen, Inc. 2021 Equity Incentive Plan aims to incentivize employees, directors and consultants who render services to the Company through the granting of stock awards, including stock options, stock appreciation right awards, restricted stock awards, restricted stock unit (“RSU”) awards, performance awards, and other stock-based awards. The following table summarizes our share-based compensation expense by the affected line on our consolidated statements of operations: Three Months Ended March 31, $ in thousands 2023 2022 Cost of services revenue $ 80 $ 563 Selling, general and administrative (9,753) 10,875 Research and development 474 1,544 Total share-based compensation expense $ (9,199) $ 12,982 The following table summarizes our share-based compensation expense by grant type: Three Months Ended March 31, $ in thousands 2023 2022 Stock options $ (12,255) $ 6,560 Restricted stock units 2,859 6,422 Employee stock purchase plan 90 — Vendor Warrants 107 — Total share-based compensation expense $ (9,199) $ 12,982 Stock Options The following table summarizes the Company’s stock option activity: $ in thousands, except share and per share data Number of Shares Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value ($) Outstanding balance as of December 31, 2022 31,203,045 $ 3.10 7.62 $ 10,725 Exercised (1,588,277) 0.15 Forfeited (10,021,087) 6.68 Expired (60,313) 2.27 Outstanding balance as of March 31, 2023 19,533,368 $ 1.50 3.51 $ 1,334 Exercisable as of March 31, 2023 14,949,494 $ 1.82 2.34 $ 1,152 During the three months ended March 31, 2023, we recognized a net reduction of $12.5 million in share-based compensation expense, included in SG&A, as a result of 9.8 million stock options forfeited in connection with the termination of our former Chief Executive Officer. As of March 31, 2023, the unrecognized compensation cost related to stock options was $1.6 million which is expected to be recognized over a weighted-average period of 1.9 years. Restricted Stock Units During the three months ended March 31, 2023, we granted 2.3 million RSU awards at a weighted average grant date fair value per share of $0.40. During the three months ended March 31, 2023, we recognized a net reduction of $0.9 million in share-based compensation expense as a result of 0.7 million RSU awards forfeited in connection with the termination of certain employees. Employee Stock Purchase Plan Under the Heliogen, Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”), eligible employees may elect to purchase the Company’s common stock at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company’s common stock. As of March 31, 2023, no shares have been issued under the 2021 ESPP. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 12—Related Party Transactions Idealab Bill Gross, our former Chief Executive Officer, also serves as the chairman of the board of directors of Idealab, a California Corporation (“Idealab”). Idealab, a holder of more than 5% of Heliogen’s outstanding voting stock through its wholly-owned subsidiary, Idealab Holdings, LLC, is a party to a lease with the Company and provides various administrative services through service agreements and certain other operational support. All expenses or amounts paid to Idealab pursuant to these agreements are reported within SG&A expense on the consolidated statements of operations. The amounts charged to us or reimbursed by us under these agreements for the three months ended March 31, 2023 and 2022 were $0.1 million and $0.1 million, respectively. In May 2021, Heliogen sub-leased a portion of its office space in Pasadena, California to Idealab. In March 2023, Heliogen entered into an amendment to the sub-lease with Idealab. The Company recognized rental revenue of $36 thousand and $39 thousand from Idealab within other income, net on our consolidated statements of operations for the three months ended March 31, 2023 and 2022, respectively. NantG Power, LLC On March 24, 2023, Heliogen entered into an agreement with NantG Power, LLC (“NantG”), an affiliated sister-company to Nant Capital LLC, a holder of more than 5% of Heliogen’s outstanding voting stock, to provide front-end concept design and R&D engineering services. The Company did not recognize any revenue from NantG during the three months ended March 31, 2023. |
Commitment and Contingencies
Commitment and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 13—Commitments and ContingenciesWe are involved in various claims and lawsuits arising in the normal course of business, including proceedings involving tort and other general liability claims and other miscellaneous claims. We recognize a liability when we believe the loss is probable and reasonably estimable. We currently believe that the ultimate outcome of such lawsuits and proceedings will not, individually or in the aggregate, have a material effect on our consolidated financial statements as of and for the three months ended March 31, 2023. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 14—Subsequent Events Stockholder Rights Plan On April 16, 2023, our Board of Directors (the “Board”) declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of the Company’s common stock to the stockholders of record as of the close of business on April 28, 2023, and adopted a limited duration stockholder rights plan, effective immediately, as set forth in the Rights Agreement, dated as of April 16, 2023 (the “Rights Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. The Rights will expire on April 17, 2024 (“Final Expiration Date”) unless the rights are earlier redeemed or exchanged by the Company. |
Organization and Basis of Pre_2
Organization and Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, these unaudited consolidated financial statements do not include all information or notes required by GAAP for annual financial statements. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for fair statement. The results reported in these unaudited consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year. These unaudited consolidated financial statements should be read in conjunction with the annual financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 29, 2023. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to inputs used to recognize revenue over time, accounting for income taxes, fair values of share-based compensation, lease liabilities, warrant liabilities, contingent consideration, goodwill impairments and long-lived asset impairments. Despite our intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions. |
Recent Accounting Standards | Recent Accounting Standards In January 2017, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which eliminates the second step of the previous two-step quantitative test of goodwill impairment. Under the new guidance, the quantitative test consists of a single step in which the carrying amount of the reporting unit is compared to its fair value. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the amount of the impairment would be limited to the total amount of goodwill allocated to the reporting unit. The guidance does not affect the existing option to perform the qualitative assessment for a reporting unit to determine whether the quantitative impairment test is necessary. The new guidance will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. The Company adopted this guidance on January 1, 2023 and it did not have a material impact on the Company’s consolidated financial statements. |
Revenue (Tables)
Revenue (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The following table provides information about disaggregated revenue: Three Months Ended March 31, $ in thousands 2023 2022 Project revenue $ 816 $ 1,991 Engineering services revenue 50 53 Total services revenue 866 2,044 Grant revenue 1,071 1,495 Total revenue $ 1,937 $ 3,539 |
Schedule of Accounts, Notes, Loans and Financing Receivable | Receivables consisted of the following: $ in thousands March 31, 2023 December 31, 2022 Trade receivables $ 1,593 $ 1,119 Grant receivables: Unbilled 6,681 5,610 Other grant receivables 1,578 1,578 Total grant receivables 8,259 7,188 Contract assets 529 560 Other receivables 265 328 Total receivables $ 10,646 $ 9,195 |
Contract with Customer, Contract Asset, Contract Liability, and Receivable | The following table outlines the activity related to contract assets, which is included in total receivables on our consolidated balance sheets: $ in thousands Balance as of December 31, 2022 $ 560 Foreign currency translation adjustments 12 Other (43) Balance as of March 31, 2023 $ 529 The following table outlines the activity related to contract liabilities: $ in thousands Balance as of December 31, 2022 $ 10,348 Payments received in advance of performance 1,464 Revenue recognized (774) Recognition of consideration payable associated with Project Warrants (76) Other 4 Balance as of March 31, 2023 $ 10,966 |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Available-for-sale Securities | The following table summarizes our investments, available-for-sale: March 31, 2023 December 31, 2022 $ in thousands Amortized Unrealized Fair Amortized Unrealized Fair Corporate bonds $ — $ — $ — $ 3,997 $ (22) $ 3,975 Commercial paper 14,927 (4) 14,923 10,837 (3) 10,834 U.S. treasury bills 65,909 (132) 65,777 82,979 (284) 82,695 Total investments, available-for-sale $ 80,836 $ (136) $ 80,700 $ 97,813 $ (309) $ 97,504 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value | The Company’s assets and liabilities measured at fair value on a recurring basis are summarized in the following table by fair value measurement level: $ in thousands Level March 31, 2023 December 31, 2022 Assets: Investments, available-for-sale 1 $ 80,700 $ 97,504 Liabilities: Public Warrants (1) 1 $ 329 $ 625 Private Warrants (1) 2 9 17 Contingent consideration (2) 3 1,478 353 ________________ (1) Included in warrant liabilities on the consolidated balance sheets. (2) Included in other long-term liabilities on the consolidated balance sheets. |
Reconciliation of Level 3 Fair Value Liabilities | The following table summarizes the activities of our Level 3 fair value measurements: Three Months Ended March 31, $ in thousands 2023 2022 Beginning balance $ 353 $ 2,009 Change in fair value (1) 1,125 14 Ending balance $ 1,478 $ 2,023 ________________ (1) The changes in the fair value of the contingent consideration are reported in other income (expense), net on our consolidated statements of operations. |
Property, Plant and Equipment (
Property, Plant and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | Major classes of property, plant and equipment, consisted of the following: $ in thousands Estimated Useful Lives in Years March 31, 2023 December 31, 2022 Leasehold improvements 5 — 7 $ 2,936 $ 2,931 Computer equipment 2 — 3 2,151 2,124 Machinery, vehicles and other equipment 5 — 10 3,739 3,528 Furniture and fixtures 2 — 5 654 646 Construction in progress 453 419 Total property, plant and equipment 9,933 9,648 Accumulated depreciation (3,156) (2,577) Total property, plant and equipment, net $ 6,777 $ 7,071 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The changes in the carrying amount of goodwill are as follows: $ in thousands Balance as of December 31, 2022 $ 1,004 Currency translation adjustments 4 Impairment (1,008) Balance as of March 31, 2023 $ — |
Schedule of Finite-Lived Intangible Assets | Intangible assets consisted of the following: March 31, 2023 December 31, 2022 $ in thousands Useful Life in Years Gross Carrying Amounts Accumulated Amortization Intangible Assets, Net Gross Carrying Amounts Accumulated Amortization and Impairment Intangible Assets, Net Acquired developed technology rights (1) 5 $ — $ — $ — $ 3,799 $ (3,799) $ — Software licenses 3 259 (124) 135 259 (103) 156 Total $ 259 $ (124) $ 135 $ 4,058 $ (3,902) $ 156 ________________ (1) Gross carrying amount for December 31, 2022 reflects currency translation adjustments of $0.4 million. |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities | Accrued expenses and other current liabilities consisted of the following: $ in thousands March 31, 2023 December 31, 2022 Payroll and other employee benefits $ 532 $ 811 Professional fees 1,309 729 Research, development and project costs 1,346 1,313 Inventory in-transit — 654 Operating lease liabilities, current portion 1,608 1,570 Other accrued expenses 1,150 525 Total accrued expenses and other current liabilities $ 5,945 $ 5,602 |
Loss Per Share (Tables)
Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | Basic and diluted loss per share (“EPS”) were as follows: Three Months Ended March 31, $ in thousands, except share and per share data 2023 2022 Numerator: Net loss $ (10,544) $ (58,968) Denominator: Weighted-average common shares outstanding 194,650,065 183,949,912 Weighted-average impact of warrants (1) 2,249,227 81,103 Denominator for basic EPS – weighted-average shares 196,899,292 184,031,015 Effect of dilutive securities — — Denominator for diluted EPS – weighted-average shares 196,899,292 184,031,015 EPS – Basic and Diluted $ (0.05) $ (0.32) ________________ (1) Warrants that have a $0.01 exercise price are assumed to be exercised when vested because common shares issued for little consideration upon exercise are included in outstanding shares for the purposes of computing basic and diluted EPS. |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following securities were excluded from the calculation of loss per share as their impact would be anti-dilutive: Three Months Ended March 31, 2023 2022 Stock options 19,533,368 37,429,240 Shares issuable related to the employee stock purchase plan 440,502 — Unvested restricted stock units 11,770,288 — Restricted shares issued upon the early exercise of unvested stock options 50,331 5,150,369 Unvested warrants 2,312,026 — Vested warrants 8,566,656 8,566,666 |
Share-based Compensation (Table
Share-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Share-based Compensation Expense | The following table summarizes our share-based compensation expense by the affected line on our consolidated statements of operations: Three Months Ended March 31, $ in thousands 2023 2022 Cost of services revenue $ 80 $ 563 Selling, general and administrative (9,753) 10,875 Research and development 474 1,544 Total share-based compensation expense $ (9,199) $ 12,982 The following table summarizes our share-based compensation expense by grant type: Three Months Ended March 31, $ in thousands 2023 2022 Stock options $ (12,255) $ 6,560 Restricted stock units 2,859 6,422 Employee stock purchase plan 90 — Vendor Warrants 107 — Total share-based compensation expense $ (9,199) $ 12,982 |
Schedule of Stock Option Activity | The following table summarizes the Company’s stock option activity: $ in thousands, except share and per share data Number of Shares Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value ($) Outstanding balance as of December 31, 2022 31,203,045 $ 3.10 7.62 $ 10,725 Exercised (1,588,277) 0.15 Forfeited (10,021,087) 6.68 Expired (60,313) 2.27 Outstanding balance as of March 31, 2023 19,533,368 $ 1.50 3.51 $ 1,334 Exercisable as of March 31, 2023 14,949,494 $ 1.82 2.34 $ 1,152 |
Organization and Basis of Pre_3
Organization and Basis of Presentation - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Net loss | $ 10,544 | $ 58,968 | $ 142,000 |
Liquidity | 119,900 | ||
Cash and cash equivalents | 39,215 | $ 63,615 | 45,719 |
Investments, available-for-sale | $ 80,700 | $ 97,504 |
Revenue - Disaggregation of Rev
Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Services revenue | $ 866 | $ 2,044 |
Grant revenue | 1,071 | 1,495 |
Total revenue | 1,937 | 3,539 |
Project revenue | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Services revenue | 816 | 1,991 |
Engineering services revenue | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Services revenue | $ 50 | $ 53 |
Revenue - Narrative (Details)
Revenue - Narrative (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |||
Services revenue | $ 866,000 | $ 2,044,000 | |
Grant revenue | 1,071,000 | 1,495,000 | |
Provision for contract losses | 370,000 | $ 33,737,000 | |
Amortization of loss on contracts | 400,000 | ||
Revenue recognized from prior performance obligation | 0 | ||
Revenue, remaining performance obligation | $ 38,500,000 | ||
Two Customers | Revenue Benchmark | Customer Concentration Risk | |||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |||
Concentration risk, percentage | 97% | 99% | |
Two Customers | Accounts Receivable | Customer Concentration Risk | |||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |||
Concentration risk, percentage | 92% | 90% | |
Project revenue | |||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |||
Services revenue | $ 816,000 | $ 1,991,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | |||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |||
Revenue, remaining performance obligation, percentage | 21% | ||
Revenue, remaining performance obligation, period | 12 months |
Revenue - Schedule of Receivabl
Revenue - Schedule of Receivables (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Trade receivables | $ 1,593 | $ 1,119 |
Total grant receivables | 8,259 | 7,188 |
Contract assets | 529 | 560 |
Other receivables | 265 | 328 |
Receivables | 10,646 | 9,195 |
Unbilled | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total grant receivables | 6,681 | 5,610 |
Other grant receivables | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total grant receivables | $ 1,578 | $ 1,578 |
Revenue - Schedule of Contract
Revenue - Schedule of Contract Assets and Liabilities (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Contract Asset [Roll Forward] | |
Contract assets with customer beginning balance | $ 560 |
Foreign currency translation adjustments | 12 |
Other | (43) |
Contract assets with customer ending balance | 529 |
Contract Liabilities [Roll Forward] | |
Contract liabilities with customer beginning balance | 10,348 |
Payments received in advance of performance | 1,464 |
Revenue recognized | (774) |
Recognition of consideration payable associated with Project Warrants | (76) |
Other | 4 |
Contract liabilities with customer ending balance | $ 10,966 |
Warrants - Narrative (Details)
Warrants - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Dec. 31, 2022 | Apr. 19, 2022 | |
Class of Warrant or Right [Line Items] | |||||
Warrants, exercise price (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||
Warrant liabilities | $ 338 | $ 338 | $ 642 | ||
Public warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 8.3 | 8.3 | |||
Private warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 0.2 | 0.2 | |||
Public and private warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Warrants, exercise price (in dollars per share) | $ 11.50 | $ 11.50 | |||
Project warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 0.9 | ||||
Warrants, exercise price (in dollars per share) | $ 0.01 | ||||
Class of warrant, fair value of warrants (in dollar per share) | $ 4.96 | ||||
Warrant liabilities | $ 4,500 | ||||
Issue of warrants | $ 100 | $ 200 | $ 800 | ||
Class of warrant or right, securities vested during period, shares (in shares) | 0.1 | 0 | 0.4 | ||
Collaboration warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 3.6 | ||||
Warrants, exercise price (in dollars per share) | $ 0.01 | ||||
Class of warrant, fair value of warrants (in dollar per share) | $ 4.96 | ||||
Prepaid warrants | $ 6,800 | $ 6,800 | |||
Prepaid warrants, current | 2,000 | 2,000 | |||
Prepaid warrants, noncurrent | 4,800 | $ 4,800 | |||
Other selling, general and administrative expense | $ 500 | $ 0 | |||
Warrants and rights outstanding, term | 3 years 4 months 24 days | 3 years 4 months 24 days | |||
Collaboration warrants | Warrant vesting, immediately | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 1.8 | ||||
Collaboration warrants | Warrant vesting, based on performance goal milestones | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 1.8 | ||||
Vendor Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Number of securities called by warrants (in shares) | 0.1 | ||||
Warrants, exercise price (in dollars per share) | $ 0.01 | ||||
Warrant liabilities | $ 300 | ||||
Other selling, general and administrative expense | $ 100 | ||||
Warrants and rights outstanding, term | 1 year |
Investments - Schedule of Inves
Investments - Schedule of Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | $ 80,836 | $ 97,813 |
Unrealized Losses | (136) | (309) |
Fair Value | 80,700 | 97,504 |
Corporate bonds | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 0 | 3,997 |
Unrealized Losses | 0 | (22) |
Fair Value | 0 | 3,975 |
Commercial paper | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 14,927 | 10,837 |
Unrealized Losses | (4) | (3) |
Fair Value | 14,923 | 10,834 |
U.S. treasury bills | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 65,909 | 82,979 |
Unrealized Losses | (132) | (284) |
Fair Value | $ 65,777 | $ 82,695 |
Investments - Narrative (Detail
Investments - Narrative (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |||
Available-for-sale securities, credit losses recognized | $ 0 | $ 0 | |
Available-for-sale securities, allowance for credit loss | $ 0 | $ 0 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Liabilities: | ||
Warrant liabilities | $ 338 | $ 642 |
Recurring | Level 1 | ||
Assets: | ||
Investments, available-for-sale | 80,700 | 97,504 |
Recurring | Level 1 | Public warrants | ||
Liabilities: | ||
Warrant liabilities | 329 | 625 |
Recurring | Level 2 | Private warrants | ||
Liabilities: | ||
Warrant liabilities | 9 | 17 |
Recurring | Level 3 | ||
Liabilities: | ||
Contingent consideration | $ 1,478 | $ 353 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Narrative (Details) | Mar. 31, 2023 $ / shares |
Public warrants | |
Class of Warrant or Right [Line Items] | |
Class of warrant, closing price of warrants | $ 0.04 |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Reconciliation of Level 3 Fair Value Liabilities (Details) - Level 3 - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | $ 353 | $ 2,009 |
Change in fair value | 1,125 | 14 |
Fair value, ending balance | $ 1,478 | $ 2,023 |
Property, Plant and Equipment -
Property, Plant and Equipment - Schedule of classes of Property, Plant and Equipment (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2022 | |
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 9,933 | $ 9,648 |
Accumulated depreciation | (3,156) | (2,577) |
Total property, plant and equipment, net | 6,777 | 7,071 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 2,936 | 2,931 |
Leasehold improvements | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 5 years | |
Leasehold improvements | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 7 years | |
Computer equipment | ||
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 2,151 | 2,124 |
Computer equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 2 years | |
Computer equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 3 years | |
Machinery, vehicles and other equipment | ||
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 3,739 | 3,528 |
Machinery, vehicles and other equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 5 years | |
Machinery, vehicles and other equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 10 years | |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 654 | 646 |
Furniture and fixtures | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 2 years | |
Furniture and fixtures | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Estimated Useful Lives in Years | 5 years | |
Construction in progress | ||
Property, Plant and Equipment [Line Items] | ||
Total property, plant and equipment | $ 453 | $ 419 |
Property, Plant and Equipment_2
Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 0.6 | $ 0.3 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Goodwill impairment loss | $ 1,008 | $ 0 | |
Amortization of intangible assets | $ 21 | $ 300 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Goodwill [Roll Forward] | ||
Goodwill, beginning balance | $ 1,004 | |
Currency translation adjustments | 4 | |
Impairment | (1,008) | $ 0 |
Goodwill, ending balance | $ 0 | $ 1,004 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amounts | $ 259 | $ 4,058 |
Accumulated Amortization | (124) | (3,902) |
Intangible Assets, Net | $ 135 | 156 |
Finite-lived intangible assets, foreign currency translation gain (loss) | 400 | |
Acquired developed technology rights | ||
Finite-Lived Intangible Assets [Line Items] | ||
Useful Life in Years | 5 years | |
Gross Carrying Amounts | $ 0 | 3,799 |
Accumulated Amortization | 0 | (3,799) |
Intangible Assets, Net | $ 0 | 0 |
Software licenses | ||
Finite-Lived Intangible Assets [Line Items] | ||
Useful Life in Years | 3 years | |
Gross Carrying Amounts | $ 259 | 259 |
Accumulated Amortization | (124) | (103) |
Intangible Assets, Net | $ 135 | $ 156 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Payables and Accruals [Abstract] | ||
Payroll and other employee benefits | $ 532 | $ 811 |
Professional fees | 1,309 | 729 |
Research, development and project costs | 1,346 | 1,313 |
Inventory in-transit | 0 | 654 |
Operating lease liabilities, current portion | 1,608 | 1,570 |
Other accrued expenses | 1,150 | 525 |
Total accrued expenses and other current liabilities | $ 5,945 | $ 5,602 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Benefit for income taxes | $ 0 | $ 610 |
Loss Per Share - Schedule of Ea
Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Numerator: | |||
Net loss | $ (10,544) | $ (58,968) | $ (142,000) |
Denominator: | |||
Weighted-average common shares outstanding (in shares) | 194,650,065 | 183,949,912 | |
Weighted-average impact of warrants (in shares) | 2,249,227 | 81,103 | |
Denominator for basic EPS – weighted-average shares (in shares) | 196,899,292 | 184,031,015 | |
Effect of dilutive securities (in shares) | 0 | 0 | |
Denominator for diluted EPS – weighted-average shares (in shares) | 196,899,292 | 184,031,015 | |
EPS – Basic (in dollars per share) | $ (0.05) | $ (0.32) | |
EPS – Diluted (in dollars per share) | (0.05) | $ (0.32) | |
Warrants, exercise price (in dollars per share) | $ 0.01 | $ 0.01 |
Loss Per Share - Schedule of An
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 19,533,368 | 37,429,240 |
Shares issuable related to the employee stock purchase plan | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 440,502 | 0 |
Unvested restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 11,770,288 | 0 |
Restricted shares issued upon the early exercise of unvested stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 50,331 | 5,150,369 |
Warrants | Unvested warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 2,312,026 | 0 |
Warrants | Vested warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation (in shares) | 8,566,656 | 8,566,666 |
Share-based Compensation - Sche
Share-based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total share-based compensation expense | $ (9,199) | $ 12,982 |
Cost of services revenue | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total share-based compensation expense | 80 | 563 |
Selling, general and administrative | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total share-based compensation expense | (9,753) | 10,875 |
Research and development | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total share-based compensation expense | $ 474 | $ 1,544 |
Share-based Compensation - Expe
Share-based Compensation - Expense by Type of Grant (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | $ (9,199) | $ 12,982 |
Vendor Warrants | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | 107 | 0 |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | (12,255) | 6,560 |
Unvested restricted stock units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | 2,859 | 6,422 |
Shares issuable related to the employee stock purchase plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | $ 90 | $ 0 |
Share-based Compensation - Sc_2
Share-based Compensation - Schedule of Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Number of Shares | ||
Options outstanding, beginning balance (in shares) | 31,203,045 | |
Options exercised (in shares) | (1,588,277) | |
Options forfeited (in shares) | (10,021,087) | |
Options expired (in shares) | (60,313) | |
Options outstanding, ending balance (in shares) | 19,533,368 | 31,203,045 |
Options exercisable (in shares) | 14,949,494 | |
Weighted Average Exercise Price ($) | ||
Options outstanding, beginning balance (in dollars per share) | $ 3.10 | |
Options exercised (in dollars per share) | 0.15 | |
Options forfeited (in dollars per share) | 6.68 | |
Options expired (in dollars per share) | 2.27 | |
Options outstanding, ending balance (in dollars per share) | 1.50 | $ 3.10 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 1.82 | |
Weighted Average Remaining Contractual Life (Years) | ||
Options outstanding, weighted average remaining contractual term | 3 years 6 months 3 days | 7 years 7 months 13 days |
Options exercisable, weighted average remaining contractual term | 2 years 4 months 2 days | |
Aggregate Intrinsic Value ($) | ||
Options outstanding, aggregate intrinsic value | $ 1,334 | $ 10,725 |
Options exercisable, aggregate intrinsic value | $ 1,152 |
Share-based Compensation - Narr
Share-based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | |
Dec. 28, 2021 | Mar. 31, 2023 | |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based payment arrangement, reversal of previously recorded expense | $ 12.5 | |
Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount | $ 1.6 | |
Unrecognized compensation cost, expected period for recognition | 1 year 10 months 24 days | |
Stock options | Former Chief Executive Officer | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock options forfeited (in shares) | 9,800,000 | |
Unvested restricted stock units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based payment arrangement, reversal of previously recorded expense | $ 0.9 | |
Granted (in shares) | 2,300,000 | |
Granted (in dollars per share) | $ 0.40 | |
Forfeited (in shares) | 700,000 | |
Shares issuable related to the employee stock purchase plan | 2021 ESPP | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation arrangement by share-based payment award, award offering period | 6 months | |
Share-based compensation arrangement by share-based payment award, discount from market price, purchase date | 15% | |
Share-based compensation arrangement by share-based payment award, shares issued in period | 0 |
Related Party Transactions - Na
Related Party Transactions - Narrative (Details) - Idealab - Affiliated entity - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Related Party Transaction [Line Items] | ||
Revenue from related parties | $ 36 | $ 39 |
Related party transaction, administrative services | ||
Related Party Transaction [Line Items] | ||
Related party transaction, amounts of transaction | $ 100 | $ 100 |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent event | Apr. 16, 2023 shares |
Subsequent Event [Line Items] | |
Share purchase right plan, number of declared dividend in shares (in shares) | 1 |
Share purchase right plan, beneficial ownership acquired, percentage | 12.50% |
Share purchase right plan, investors beneficial ownership acquired, percentage | 20% |